It is a hundred years since the BCG vaccine, the only registered vaccine proven to offer some protection against tuberculosis (TB), was first used in people. Now researchers in South Africa are at the forefront of clinical trials testing experimental new TB vaccines. Adele Baleta reports.
While likely millions of people in South Africa have latent tuberculosis (TB) infection, only between three and 10% of these people ever fall ill with TB. Cutting-edge research conducted in South Africa has now taken us a significant step closer to a test that can predict who will and who will not fall ill with TB. Such a test, if simple and affordable, could potentially revolutionise TB prevention efforts.